Merck's KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy After Surgery as Adjuvant Treatment for Patients With Resectable Stage II, IIIA or IIIB NSCLC
Portfolio Pulse from
Merck's KEYTRUDA has been approved in China for use in combination with chemotherapy as a neoadjuvant treatment and as monotherapy post-surgery for certain NSCLC patients.
December 16, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Merck's KEYTRUDA has received approval in China for a new treatment regimen for NSCLC, potentially expanding its market and increasing sales.
The approval of KEYTRUDA in China for a new treatment regimen for NSCLC patients could lead to increased sales and market expansion for Merck, positively impacting its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100